search
Back to results

Virtual Reality Mask During in Utero Surgical Procedures (VIRTUALFETO)

Primary Purpose

Fetofetal Transfusion, Analgesia

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Virtual reality mask
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Fetofetal Transfusion focused on measuring feotoscopy, virtual reality, fetal sugery

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged more than 18 years old
  • Complicated biamniotic monochorionic twin pregnancy
  • Indication for fetal surgery: Fetoscopy laser photocoagulation or Selective termination of pregnancy.
  • Patient Consent
  • Affiliation to a social security coverage

Exclusion Criteria:

  • No understanding of the French language
  • Visually impaired or hard of hearing
  • Participation in another intervention research
  • Patient under State medical aid
  • Psychiatric disorders (schizophrenia, schizophreniform disorders)
  • Major neurocognitive disorders (dementias)
  • Migraine helped a basic treatment
  • Epilepsy with treatment
  • Pacemaker carrier
  • With lesions on the scalp

Sites / Locations

  • Hannane BOUCHGHOULRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

virtual reality mask

Arm Description

During the prior anesthesia consultation, the patient is informed of the possibility within the framework of the study of benefiting from analgesia with disconnection by a virtual reality mask, associated with local anesthesia. The patient will be explained that in the event of pain despite the virtual reality mask and local anesthesia, administration of remifentanil will be possible

Outcomes

Primary Outcome Measures

the orimary outcome is the success of the virtual reality mask for analgesia defined by the absence of pain expressed by the woman (no administration of morphine (remifentanil)).
"administration of remifentanil: no=success; yes=failure".

Secondary Outcome Measures

Maternal anxiety
Anxiety will be assessed by a Visual Analog Scale before and immediately after the intervention (0 being no anxiety and 10 being extremely intense anxiety). An assessment of anxiety using a visual analog scale will be performed before the procedure on arrival in the theatre room and immediately after the procedure after removing the VR mask. This scale provides a score from 0 to 10 to measure the anxiety felt by the patient. This before-after anxiety assessment is used to study the variation in the patient's anxiety between the beginning of the procedure and the end of the procedure.
The total dose of remifentanil in microgram (in relation to the total duration of the intervention) in case of administration of remifentanil
Overall maternal satisfaction
Evaluation of the experience of the intervention and of maternal satisfaction will be performed using an EVAN-LR questionnaire. The EVAN-LR questionnaire is a validated satisfaction questionnaire for patients who remained conscious during the procedure. One of the strengths of this scale is its applicability in current practice as only 19 items need to be completed by the patient. The average filling time of the EVAN-LR is five minutes. For each item, the patient may check one of the following boxes: Not at all/ A little bit/ Moderately/ A lot/ Very much.
Side effects
nausea, dizziness, headaches, visual disturbances, discomfort
The rate of patients with a chosen virtual reality theme

Full Information

First Posted
April 29, 2021
Last Updated
December 26, 2022
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT04917211
Brief Title
Virtual Reality Mask During in Utero Surgical Procedures
Acronym
VIRTUALFETO
Official Title
Use of a Virtual Reality Mask in the Reduction of Pain and Anxiety During in Utero Surgical Procedures
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 29, 2022 (Actual)
Primary Completion Date
May 1, 2024 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
"The virtual reality mask is an innovative technique, alternative to pharmacological medicine that would allow, in addition to its action on pain, to reduce anxiety and thus increase patient satisfaction by improving their experience of a risky situation. The therapeutic effects of the virtual reality mask are based on a distractive effect with attentive capture, an emotional effect due to ludic aspect and positive suggestion, and a behavioral effect. In utero fetoscopy is a potentially painful procedure, particularly at the beginning of the procedure due to the introduction of a fetoscopy trocar in the amniotic cavity through the patient's uterus. It also generates anxiety in mothers because of the risks associated with the pathology and the procedure. This research focuses on the use of a virtual reality mask in the reduction of pain and anxiety during in utero surgical procedures. The study is presented and proposed to the patient during the expert ultrasound examination by the obstetrician-gynecologist. Then the modalities are detailed by the anesthetist during the anesthesia consultation before the surgery. The patient is included in the study after the consent is signed. During the anesthesia consultation, the patient is informed of the possibility of analgesia through a virtual reality mask, associated with local anesthesia. It is explained that in case of pain despite the virtual reality mask and local anesthesia, remifentanil administration remains possible. During the anesthesia consultation, the patient's initial state of anxiety is assessed by the score Amsterdam Preoperative Anxiety and Information Scale. The procedure takes place in the theatre room. Upon arrival in the theatre room (preoperative), an evaluation of the anxiety level is performed using a visual analog scale. The virtual reality mask is applied by the anesthesia team before skin disinfection and the placement of sterile drapes. During the procedure, a local anesthesia (non-adrenaline Xylocaine 1%) is performed as usual in order to insert the trocar in the amniotic cavity (diameter 3.5mm) which will be used to introduce the intra-amniotic fetoscope. If during the procedure, the patient feels pain, agitation, pain-related discomfort, morphine analgesia (Intravenous Remifentanil which means Intravenous Anesthesia with Objective Concentration) may be administered by the anesthesia team. Immediately after the procedure, the virtual reality mask will be removed.
Detailed Description
"The use of the virtual reality mask associated with local anesthesia during in utero fetal surgery procedures by fetoscopy in the treatment of complications of monochorionic twin pregnancies, could be an alternative to the use of intravenous remifentanil associated with local anesthesia. It would allow analgesia and reduction of patient anxiety, thus simplifying the procedure for both patients and surgeons. The virtual reality mask is an innovative technique, alternative to pharmacological medicine that would allow, in addition to its action on pain, to reduce anxiety and thus increase patient satisfaction by improving their experience of a risky situation. The therapeutic effects of the virtual reality mask are based on a distractive effect with attentive capture, an emotional effect due to ludic aspect and positive suggestion, and a behavioral effect. The virtual reality mask has almost never been studied in a pregnant population, particularly in the context of in utero procedures associated with risks of fetal loss that further increase anxiety. In utero fetoscopy is a potentially painful procedure, particularly at the beginning of the procedure due to the introduction of a fetoscopy trocar in the amniotic cavity through the patient's uterus. It also generates anxiety in mothers because of the risks associated with the pathology and the procedure. This research focuses on the use of a virtual reality mask in the reduction of pain and anxiety during in utero surgical procedures. This is a prospective cohort study including pregnant women who have a complicated monochorionic twin pregnancy with an indication for fetal surgery (laser photocoagulation fetoscopy or Selective Termination of Pregnancy). The objective is to evaluate the success rate of the virtual reality mask for analgesia during fetoscopy in case of monochorionic twin pregnancies complicated. The success of the virtual reality mask for analgesia is defined by the absence of pain expressed by the woman (no administration of morphine (remifentanil)). The primary outcome is the administration or not of remifentanil. The secondary objectives are to evaluate firstly the variation in maternal anxiety when using the virtual reality mask, secondly the pain during the intervention and thirdly the maternal satisfaction. The study is presented and proposed to the patient during the expert ultrasound examination by the obstetrician-gynecologist. Then the modalities are detailed by the anesthetist during the anesthesia consultation before the surgery. The presentation of the study and the signature of the consent can be done within two weeks prior to the procedure. The patient is included in the study after the consent is signed. During the anesthesia consultation, the patient is informed of the possibility of analgesia through a virtual reality mask, associated with local anesthesia. It is explained that in case of pain despite the virtual reality mask and local anesthesia, remifentanil administration remains possible. During the anesthesia consultation, the patient's initial state of anxiety is assessed by the APAIS score (Amsterdam Preoperative Anxiety and Information Scale). This is a validated score for the evaluation of patients' anxiety prior to a procedure. A score higher than 10 out of 20 indicates a high level of anxiety and helps to identify the most anxious patients. This score will therefore allow to evaluate the initial anxiety state by identifying two groups of patients according to their initial anxiety level: high (score strictly greater than 10) and normal (score less than or equal to 10), but also the mean initial anxiety score. The procedure takes place in the theatre room. Upon arrival in the theatre room (preoperative), an evaluation of the anxiety level is performed using a visual analog scale. The virtual reality mask is applied by the anesthesia team before skin disinfection and the placement of sterile drapes. During the procedure, a local anesthesia (non-adrenaline Xylocaine 1%) is performed as usual in order to insert the trocar in the amniotic cavity (diameter 3.5mm) which will be used to introduce the intra-amniotic fetoscope. This is a painful procedure because of the insertion of the trocar that crosses the abdominal wall, the subcutaneous tissue and the myometrium. Therefore, this justifies subcutaneous anesthesia up to the uterine serosa. If during the procedure, the patient feels pain, agitation, pain-related discomfort, morphine analgesia (Intravenous Remifentanil in IVAOC mode which means Intravenous Anesthesia with Objective Concentration) may be administered by the anesthesia team. Immediately after the procedure, the virtual reality mask will be removed. An evaluation of anxiety is performed using visual analog scale for anxiety. Maternal anxiety is thus evaluated by a score before and immediately after the intervention (variation in anxiety between before and after the intervention) (0 being the absence of anxiety and 10 being extremely intense anxiety). Moreover, the overall pain is assessed using visual analog scale for pain. Maternal pain will also be quantified in 2 ways: by the total dose of remifentanil (in relation to the total duration of the procedure) if remifentanil is administered and by a visual analog scale graded from 0 to 10 at the end of the intervention (0 being the absence of pain and 10 being the maximum pain imaginable). Lastly, the side effects sought are: nausea, dizziness, headaches, visual disturbances, discomfort. The day after the intervention, an evaluation of the experience of the intervention and of maternal satisfaction will be performed using an EVAN-LR questionnaire. The EVAN-LR questionnaire is a validated satisfaction questionnaire for patients who remained conscious during the procedure. One of the strengths of this scale is its applicability in current practice as only 19 items need to be completed by the patient. The average filling time of the EVAN-LR is five minutes. For each item, the patient may check one of the following boxes: Not at all/ A little bit/ Moderately/ A lot/ Very much. If this was not possible the day after the operation, it is possible to fill it up to the second day after the operation. Patient participation ends after filling out the satisfaction questionnaire on day 1 or at the latest on day 2 after intervention. Patients will then be managed according to the usual practice. The success rate of the virtual reality mask expected according to our experience is around 95%. In order to meet the objective of estimating this success rate with a good precision, the number of patients to be recruited is 73 patients having used the mask. This allows a precision of ±5.0% if the percentage of success is 95%, which seems a quite acceptable precision. In order to have useful data for a future therapeutic trial where there will be controls, the same data as for the participating women will be recorded for the women who refused the mask. Between 10 and 15 women who refused the virtual reality mask are expected to participate."

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fetofetal Transfusion, Analgesia
Keywords
feotoscopy, virtual reality, fetal sugery

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
virtual reality mask
Arm Type
Experimental
Arm Description
During the prior anesthesia consultation, the patient is informed of the possibility within the framework of the study of benefiting from analgesia with disconnection by a virtual reality mask, associated with local anesthesia. The patient will be explained that in the event of pain despite the virtual reality mask and local anesthesia, administration of remifentanil will be possible
Intervention Type
Procedure
Intervention Name(s)
Virtual reality mask
Intervention Description
"The virtual reality mask is a mask with a screen that is put on the patient's face in the theatre before the surgery. It offers 3D scenarios of about 20 to 40 minutes on five different themes (the Zen garden, the mountain, the forest, the beach, the scuba diving) with music. The video-headset, equipped with head movement sensors, allows the 3D vision of a natural virtual world and the audio-headset emits sounds adapted to the virtual world and music therapy. The RV mask, via multi-sensorial immersion, focuses on two therapeutic targets which are pain and anxiety. It is a non-drug approach ""cousin"" to hypnosis. Its therapeutic effects are based on a distractive effect: attentive capture, an emotional effect: playfulness and positive suggestion, and a behavioral effect: the patient participates and is an actor in his care. "
Primary Outcome Measure Information:
Title
the orimary outcome is the success of the virtual reality mask for analgesia defined by the absence of pain expressed by the woman (no administration of morphine (remifentanil)).
Description
"administration of remifentanil: no=success; yes=failure".
Time Frame
2 days after the end of intervention
Secondary Outcome Measure Information:
Title
Maternal anxiety
Description
Anxiety will be assessed by a Visual Analog Scale before and immediately after the intervention (0 being no anxiety and 10 being extremely intense anxiety). An assessment of anxiety using a visual analog scale will be performed before the procedure on arrival in the theatre room and immediately after the procedure after removing the VR mask. This scale provides a score from 0 to 10 to measure the anxiety felt by the patient. This before-after anxiety assessment is used to study the variation in the patient's anxiety between the beginning of the procedure and the end of the procedure.
Time Frame
Baseline and immediately after the intervention
Title
The total dose of remifentanil in microgram (in relation to the total duration of the intervention) in case of administration of remifentanil
Time Frame
2 days after the end of intervention
Title
Overall maternal satisfaction
Description
Evaluation of the experience of the intervention and of maternal satisfaction will be performed using an EVAN-LR questionnaire. The EVAN-LR questionnaire is a validated satisfaction questionnaire for patients who remained conscious during the procedure. One of the strengths of this scale is its applicability in current practice as only 19 items need to be completed by the patient. The average filling time of the EVAN-LR is five minutes. For each item, the patient may check one of the following boxes: Not at all/ A little bit/ Moderately/ A lot/ Very much.
Time Frame
The satisfaction questionnaire is filled out on day 1 or at the latest on day 2 after intervention
Title
Side effects
Description
nausea, dizziness, headaches, visual disturbances, discomfort
Time Frame
2 days after the end of intervention
Title
The rate of patients with a chosen virtual reality theme
Time Frame
2 days after the end of intervention

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged more than 18 years old Complicated biamniotic monochorionic twin pregnancy Indication for fetal surgery: Fetoscopy laser photocoagulation or Selective termination of pregnancy. Patient Consent Affiliation to a social security coverage Exclusion Criteria: No understanding of the French language Visually impaired or hard of hearing Participation in another intervention research Patient under State medical aid Psychiatric disorders (schizophrenia, schizophreniform disorders) Major neurocognitive disorders (dementias) Migraine helped a basic treatment Epilepsy with treatment Pacemaker carrier With lesions on the scalp
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hanane BOUCHGHOUL
Phone
01 45 21 77 80
Email
hanane.bouchghoul@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Marie-Victoire SENAT
Phone
01 45 21 77 64
Email
marie-victoire.senat@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hanane BOUCHGHOUL
Organizational Affiliation
Public Assistance of Paris Hospitals
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hannane BOUCHGHOUL
City
Le Kremlin-Bicêtre
ZIP/Postal Code
94270
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hannane BOUCHGHOUL, PH
Phone
05.56.79.56.79
Email
hanane.bouchghoul@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Marie-Victoire SENAT, Pu-PH
Phone
01 45 21 77 64
Email
marie-victoire.senat@aphp.fr

12. IPD Sharing Statement

Learn more about this trial

Virtual Reality Mask During in Utero Surgical Procedures

We'll reach out to this number within 24 hrs